Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784617 | 0.82 | MGAM (0.38) | TSHRGAAHSD17B10MGAMSI | |
| SCHEMBL18307344 | 0.81 | BRD4 (0.40) | BRD4NR1H2TSHRGAAHSD17B10 | |
| Hydrochloric Acid SCHEMBL21496927 | 0.81 | MGAM (0.36) | TSHRGAAHSD17B10MGAMSI | |
| Hydrochloric Acid SCHEMBL18299879 | 0.80 | BRD4 (0.39) | BRD4NR1H2TSHRGAAHSD17B10 | |
| SCHEMBL22483469 | 0.76 | BRD4 (0.44) | BRD4NR1H2TSHRGAAHSD17B10 | |
| SCHEMBL24785839 | 0.76 | SLC6A12 (0.41) | ALDH1A1 | |
| SCHEMBL16969218 | 0.75 | BRD4 (0.38) | BRD4 | |
| SCHEMBL31196434 | 0.75 | BRD4 (0.38) | BRD4NR1H2TSHRGAAHSD17B10 | |
| Hydrochloric Acid SCHEMBL21458243 | 0.75 | SLC6A12 (0.43) | ALDH1A1 | |
| SCHEMBL13240741 | 0.75 | BRD4 (0.43) | BRD4TSHRGAAHSD17B10MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |